ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole

  • Martin Smollich, Martin Götte, Jeanett Fischgräbe, Luciana F. Macedo, Angela Brodie, Shiuan Chen, Isabel Radke, Ludwig Kiesel, Pia Wülfing
  • Breast Cancer Research and Treatment, November 2009, Springer Science + Business Media
  • DOI: 10.1007/s10549-009-0644-2

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Professor Martin Götte